BioXcel Therapeutics, Inc. short interest in 2021
In 2021, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 15.07% of shares outstanding on 15 Jan 2021 to 6.18% on 31 Dec 2021, a change of -8.89 percentage points. The year's high was 15.09% on 15 Mar 2021 and its low 6.18% on 31 Dec 2021, averaging 10.56% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.82 days on 28 May 2021. Full history: BioXcel Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 15.07% (15 Jan 2021)
- End of year
- 6.18% (31 Dec 2021)
- Change
- -8.89 pp
- High
- 15.09% (15 Mar 2021)
- Low
- 6.18% (31 Dec 2021)
- Average
- 10.56%
- Highest days to cover
- 17.82 (28 May 2021)
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 15.07% | 5.09 | |
| 29 Jan 2021 | 13.86% | 7.00 | |
| 12 Feb 2021 | 14.65% | 6.35 | |
| 26 Feb 2021 | 14.81% | 8.61 | |
| 15 Mar 2021 | 15.09% | 8.17 | |
| 31 Mar 2021 | 13.65% | 6.88 | |
| 15 Apr 2021 | 14.86% | 6.20 | |
| 30 Apr 2021 | 13.71% | 11.91 | |
| 14 May 2021 | 12.92% | 9.53 | |
| 28 May 2021 | 12.52% | 17.82 | |
| 15 Jun 2021 | 11.83% | 11.60 | |
| 30 Jun 2021 | 12.10% | 4.03 | |
| 15 Jul 2021 | 10.65% | 6.00 | |
| 30 Jul 2021 | 9.59% | 6.91 | |
| 13 Aug 2021 | 7.95% | 8.88 | |
| 31 Aug 2021 | 7.31% | 7.65 | |
| 15 Sep 2021 | 6.79% | 8.13 | |
| 30 Sep 2021 | 6.59% | 7.15 | |
| 15 Oct 2021 | 6.19% | 6.02 | |
| 29 Oct 2021 | 6.69% | 9.63 | |
| 15 Nov 2021 | 6.40% | 5.53 | |
| 30 Nov 2021 | 7.09% | 5.83 | |
| 15 Dec 2021 | 7.00% | 5.34 | |
| 31 Dec 2021 | 6.18% | 6.04 |
See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.